New York State Common Retirement Fund
KNTE

New York State Common Retirement Fund’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

New York State Common Retirement Fund’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-210
Closed -$636 – 3411
2023
Q2 		$636 Sell
210
-2,374
-92% -$9.15K ﹤0.01% 3348
2023
Q1 		$16.1K Sell
2,584
-16,257
-86% -$99K ﹤0.01% 3152
2022
Q4 		$115K Sell
18,841
-41
-0.2% -$334 ﹤0.01% 2918
2022
Q3 		$226K Buy
18,882
+103
+0.5% +$1.35K ﹤0.01% 2727
2022
Q2 		$237K Sell
18,779
-25
-0.1% -$233 ﹤0.01% 2718
2022
Q1 		$212K Sell
18,804
-13
-0.1% -$143 ﹤0.01% 2801
2021
Q4 		$333K Buy
18,817
+8,279
+79% +$175K ﹤0.01% 2652
2021
Q3 		$243K Sell
10,538
-2,573
-20% -$56K ﹤0.01% 2840
2021
Q2 		$305K Buy
13,111
+5,811
+80% +$148K ﹤0.01% 2839
2021
Q1 		$227K Buy
+7,300
New +$254K ﹤0.01% 2788

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

New York State Common Retirement Fund's KNTE Position: Q3 2023 in Review

New York State Common Retirement Fund sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 210 shares — an estimated $636 sold.

New York State Common Retirement Fund first reported a position in KNTE in Q1 2021 and held it in 10 quarters. The position peaked at $333K in Q4 2021. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • New York State Common Retirement Fund reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • New York State Common Retirement Fund sold 210 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $636.
  • New York State Common Retirement Fund first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • New York State Common Retirement Fund's Kinnate Biopharma Inc. Common Stock position peaked at $333K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on New York State Common Retirement Fund's 13F filing for Q3 2023, filed 7 Nov 2023.